 |
인쇄하기
취소
|
Celltrion’s Remsia in spotlight
Celltrion’s biosimilar monoclonal antibody Remsima (infliximab) is currently under the industry spotlight after the company gained market authorization from the European Commission on August 28.
The clinical report of Remsima, a biosimilar version of Remicade, was presented and praised as a real biosimilar drug at the Symposium of the Asia Pacific League of Associations for Rheumatology (APL...
The clinical report of Remsima, a biosimilar version of Remicade, was presented and praised as a real biosimilar drug at the Symposium of the Asia Pacific League of Associations for Rheumatology (APL...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.